The adult trial failure is a setback for the HSCT-TMA program, but the pediatric path forward is intact with regulatory filings underway. The stock may see limited downside given the niche indication and Ultomiris's existing approvals in larger markets. Monitor health authority feedback on the adult indication and any pediatric approval timelines.
Price Chart
Executive Summary
AstraZeneca reported Phase III results for Ultomiris in HSCT-TMA: the adult/adolescent trial (ALXN1210-TMA-313) failed to meet its primary endpoint of event-free survival, while the pediatric trial (ALXN1210-TMA-314) showed previously disclosed clinically meaningful overall survival (87.2% at 26 weeks). The company is advancing regulatory filings for the pediatric indication, but the adult indication faces an uncertain path pending ongoing health authority discussions.
Key Facts
- Ultomiris did not achieve statistical significance for the primary endpoint (event-free survival through 26 weeks) in the Phase III ALXN1210-TMA-313 trial in adults and adolescents with HSCT-TMA.
- In the pediatric Phase III ALXN1210-TMA-314 trial, Ultomiris demonstrated clinically meaningful overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks (previously disclosed).
- Alexion, AstraZeneca Rare Disease, is advancing regulatory filings for Ultomiris in pediatric HSCT-TMA based on these results and an external control study.
- Ultomiris has Orphan Drug Designation in the US and Japan for HSCT-TMA and Breakthrough Therapy designation from the FDA for pediatric patients with HSCT-TMA.
- HSCT-TMA is estimated to affect fewer than 6,000 people in the US.
Financial Impact
No financial figures provided in the filing; the indication addresses a small patient population (<6,000 in the US), so the revenue contribution is likely minimal relative to AstraZeneca's total revenue.
Risk Factors
- Regulatory path for the adult indication remains uncertain; health authorities may require additional data or reject the indication.
- Competition from other complement inhibitors or emerging therapies for HSCT-TMA.
- Narrow patient population limits commercial upside; clinical adoption may be slow without clear efficacy data in adults.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006897 |
| Document: 0001654954-26-006897-index-headers.html | 0001654954-26-006897 |
| Document: 0001654954-26-006897-index.html | 0001654954-26-006897 |
| Document: 0001654954-26-006897.txt | 0001654954-26-006897 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access